Other Events ·
C4 Therapeutics presents further analysis of Phase 1 trial data for cemsidomide in combination with dexamethasone at EHA 2026 Congress
CCCCC4 Therapeutics, Inc.
C4 Therapeutics, Inc. announced the release of further analysis from its fully enrolled Phase 1 trial of cemsidomide, an oral IKZF1/3 degrader, used in combination with dexamethasone for treating relapsed/refractory multiple myeloma. This data will be presented at the European Hematology Association 2026 Congress. C4 Therapeutics, Inc. is a biotechnology company focused on ability-based protein degradation.</div>